
Advaxis ADXS
Geschäftsbericht 2023
hinzugefügt 16.04.2024
Land |
|
IPO-Jahr |
- |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ CAPITAL |
Anteile |
6.02 M |
Marktkapitalisierung |
$ 45.9 M |
EBITDA (LTM) |
$ -33.9 M |
P/E (LTM) |
- |
P/S (LTM) |
322.91 |
EPS (LTM) |
-8.53 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Aligos Therapeutics
ALGS
|
$ 8.64 | 8.07 % | $ 85.4 M | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.66 | -1.48 % | $ 8.81 B | Nasdaq Capital Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 21.36 | 4.86 % | $ 998 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.47 | 5.0 % | $ 378 M | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 2.92 | - | $ 4.81 M | NYSE American | ||
|
Aquestive Therapeutics
AQST
|
$ 4.19 | 2.7 % | $ 448 M | Nasdaq Global Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.12 | -0.37 % | $ 3.07 B | Nasdaq Global Select Market,SPB | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 32.59 | 1.09 % | $ 2.16 B | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.47 | -1.34 % | $ 391 M | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 4.25 | 8.35 % | $ 286 B | Nasdaq Capital Market | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Esperion Therapeutics
ESPR
|
$ 2.22 | 2.3 % | $ 461 M | Nasdaq Global Market,SPB | ||
|
Evogene Ltd.
EVGN
|
$ 0.82 | 1.13 % | $ 27.9 M | Nasdaq Global Market | ||
|
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 3.2 | 2.24 % | $ 322 M | Nasdaq Global Select Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market |